David J. Andorsky

Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide + Rituximab (R2) Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin

Introduction:Patients with relapsed indolent NHL (iNHL) have limited standard treatment options. Lenalidomide combined with rituximab (R ) has shown complimentary clinical activity and is...

Jung R. Ahn ;

Ju Li ;

Mathias D. Rummel ;

Jeff P. Sharman ;

Frederick Lansigan ;

David J. Andorsky ;

Morton Coleman ;

Yacoub Abdulraheem ;

Jason M. Melear ;

Suzanne R. Fanning ;

Kathryn S. Kolibaba ;

Chris Reynolds ;

Grzegorz S. Nowakowski ;

Mecide Gharibo ;

11/04/2022

Conference Coverage

Updated Findings on Efficacy and Safety of Tazemetostat Plus Lenalidomide and Rituximab for Patients With R/R FL

01/10/2024

David J. Andorsky ;

At the 65th ASH Annual Meeting, David Andorsky, MD, discussed updated findings from the Symphony-1 trial after a 22.5-month follow-up.

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Conference Coverage

Asciminib Continues to Demonstrate Efficacy and Tolerability Among Patients With CML in Chronic Phase

01/10/2024

David J. Andorsky ;

At the 65th ASH Annual Meeting, David Andorsky, MD, discussed an interim analysis of the AIM4CML trial, which indicated that asciminib treatment continued to demonstrate efficacy and tolerability among patients with CML chronic phase.

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology